Lipomax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipomax

Property Description
Active Ingredient Atorvastatin
Form Film-coated Tablets
Pharmacological Class Statin (HMG-CoA Reductase Inhibitor)
Origin Synthetic
General Purpose Lipid-modifying agent (to lower cholesterol)

What Type of Medicine is Lipomax (Atorvastatin)?

Lipomax is a synthetic, prescription-only medicinal product whose active chemical substance is Atorvastatin. This drug is formally classified as a Statin, or more specifically, an HMG-CoA Reductase Inhibitor. The medication is intended for oral administration and is supplied in the form of a film-coated tablet. This pharmacological class is clinically recognized for its high efficacy in regulating blood lipid levels, defining Lipomax as a dedicated lipid-modifying agent used for systemic action to address imbalances in blood fats.

Composition and General Purpose of the Drug

The physical product is a single-ingredient medication containing Atorvastatin Calcium, the specific salt form chosen for stability and optimal absorption. Unlike combination therapies that pair different mechanisms, Lipomax provides a focused approach solely through the action of the statin component. The overarching general purpose of this drug is to reduce pathologically high levels of fatty substances, particularly low-density lipoprotein (LDL) cholesterol, in the bloodstream. Atorvastatin is used to decrease the amounts of fatty substances in the blood, reflecting its general use in adults with high cholesterol. By restoring a healthier lipid profile, the treatment supports the vital benefit of cardiovascular risk prevention in the long term.

The Mechanism's Core Concept

The primary action of Lipomax is achieved by competitively inhibiting a key enzyme within the liver known as HMG-CoA Reductase. The inhibition of HMG-CoA reductase is the fundamental mechanism that leads to reduced cholesterol biosynthesis. This means the medication substantially reduces the body's internal cholesterol production, providing a systemic method for lowering harmful lipoproteins. The benefit is supported by pharmacological evidence showing its effectiveness in regulating these key processes.

Regulatory References

  1. Atorvastatin: MedlinePlus Drug Information

What side effects are possible with Lipomax?

Possible Side Effects and Safety Information: Lipomax (Atorvastatin)

This section outlines the adverse reactions and safety constraints for Lipomax, containing Atorvastatin, as documented in authoritative government regulatory labels (e.g., FDA Prescribing Information, EMA SmPC). This information is descriptive and not a substitute for professional medical guidance.

Documented Adverse Reactions

Side effects are officially classified by frequency:

Frequency Examples of Documented Side Effects
Common Nasopharyngitis, Myalgia (muscle pain), Arthralgia (joint pain), Diarrhea, Urinary Tract Infection.
Rare Rhabdomyolysis, Myositis, Cholestasis, Tendonopathy.
Very Rare Anaphylaxis, Hepatic Failure, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN).

Adverse effects primarily involve the Musculoskeletal and Connective Tissue Disorders and Hepatobiliary Disorders organ systems.

Serious Safety Considerations

The most serious adverse reactions documented in regulatory sources include Rhabdomyolysis (a severe muscle breakdown that can lead to kidney damage), Hepatic Failure (fatal and non-fatal cases reported), and severe Hypersensitivity reactions like Anaphylaxis. The label also notes the risk of Immune-Mediated Necrotizing Myopathy (IMNM).

Population-Specific Restrictions

Lipomax is Contraindicated in specific populations as stated in official labeling. This includes all pregnant women, women who are trying to become pregnant, and women who are breastfeeding. It is also Contraindicated in individuals with Active Liver Disease or unexplained, persistent elevations of serum transaminases (liver enzymes).

Safety-Related Limitations

Official labels require monitoring of liver function tests before initiating therapy and when clinically indicated. Treatment must be discontinued if creatine kinase (CK) levels are found to be markedly elevated or if Rhabdomyolysis is diagnosed or suspected.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The information below summarizes the official, regulatory documentation regarding an overdose of Lipomax (Atorvastatin) and is strictly non-advisory.

Documented Overdose Profile

Official prescribing information confirms that there are no specific symptoms or clinical signs uniquely documented for an Atorvastatin overdose. Consequently, management focuses on the potential for severe, dose-related toxicity.

The most serious concern in a high-exposure scenario is the risk of rhabdomyolysis, a potentially life-threatening breakdown of muscle tissue. This condition can lead to secondary complications, including acute kidney injury.

Overdose Management Fact Regulatory Statement
Antidote No specific antidote is available.
Clearance Hemodialysis is not expected to significantly enhance drug clearance due to extensive protein binding.
Required Action Management must be symptomatic and supportive.

When to Seek Immediate Medical Attention

Urgent medical help must be sought immediately if symptoms indicative of severe muscle injury occur. This includes unexplained muscle pain, tenderness, or weakness, particularly if these symptoms are accompanied by fever or general malaise. These symptoms require immediate attention as they may signal rhabdomyolysis.

Therapeutic Uses of Lipomax

What Lipomax Treats: Main Uses and Benefits

For the specific variant Thalidomide Lipomed, the therapeutic area relevant to its approved use is commonly used in complex systemic care contexts. It is relevant for the treatment of multiple myeloma and its associated manifestations. This represents a condition characterized by periods of heightened symptoms and involving episodic or fluctuating manifestations.

This supportive care is commonly used in clinical settings that involve acute or unstable symptom patterns, helping address symptom clusters that may become intense or disruptive. It may assist with managing symptoms that create noticeable physiological strain and are linked to organ-specific functional stress. As part of supportive symptom management, the principle is that:

“The therapy contributes to improved comfort during periods of heightened symptoms.”

This approach supports patients during difficult episodes by easing distress and assists with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for symptoms related to systemic imbalance

Regulatory References

  1. European Medicines Agency (EMA) Thalidomede Lipomed Overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lipomax (Atorvastatin) — Official Regulatory Information

Lipomax (Atorvastatin) eligibility is strictly defined by regulatory bodies based on a patient's health status and age.


Eligibility Scope

Classification Population or Condition
Contraindicated Active liver disease or unexplained persistent serum transaminase elevations (exceeding 3x ULN).
Known hypersensitivity to atorvastatin or any component of the medication.
Pregnancy or breastfeeding (Lactation).
Women of child-bearing potential not using appropriate contraception.
Allowed Adults with hyperlipidemia and for cardiovascular event prevention.
Pediatric patients aged 10 years and older with Heterozygous or Homozygous Familial Hypercholesterolemia.
Restricted Use Patients with predisposing factors for myopathy (e.g., uncontrolled hypothyroidism, renal impairment, advanced age >65 years).
Concomitant use with certain antivirals (e.g., glecaprevir/pibrentasvir) is prohibited or severely restricted.

Age-Related Eligibility

Treatment is not established and not indicated for pediatric patients below the age of 10 years. For older adults (aged 70 and over), efficacy is generally similar to the general population, although advanced age is cited as a risk factor for muscle-related toxicity.


Connection to the overall eligibility profile

Official regulatory documents define Lipomax eligibility through absolute contraindications tied to reproductive status and liver function. Use is further defined by age limits, restricting treatment initiation in children under 10. For all other allowed populations, use is conditional, requiring caution when risk factors for muscle toxicity are present.

What should I know about interactions with other medicines?

Official Interaction Profile of Lipomax (Atorvastatin)

The official interaction profile of Lipomax (Atorvastatin) is structured by documented effects on metabolic pathways and the potential for additive adverse outcomes, all strictly based on government regulatory documentation.

Formal Prohibitions and Exposure Effects Co-administration with Ciclosporin and the systemic use of Fusidic Acid are formally classified as contraindicated due to the risk of a significant increase in Atorvastatin plasma concentrations. This exposure increase is fundamentally a pharmacokinetic interaction mediated by interference with the CYP3A4 enzyme and the OATP1B1 uptake transporter. Strong CYP3A4 inhibitors, such as Clarithromycin, are documented to raise Atorvastatin levels, while inducers, including Rifampicin and the herbal product St. John's Wort, are documented to reduce systemic exposure.

Additive Risk and Timing Constraints The regulatory profile highlights additive pharmacodynamic risk. Concurrent use with Fibrates or high-dose Niacin is documented to increase the risk of adverse skeletal muscle effects. Specific timing constraints exist: Rifampicin must be co-administered simultaneously to mitigate interaction effects, and a mandatory cessation of Atorvastatin is required following systemic Fusidic Acid use. Additionally, the consumption of large quantities of Grapefruit Juice is explicitly documented to increase the drug's plasma exposure. Interaction relevance may be heightened in populations with hepatic impairment.

Mechanism of Action

Competitive Inhibition of Hepatic Cholesterol Synthesis

The drug's primary action involves acting as a competitive inhibitor of HMG-CoA Reductase, a crucial, rate-limiting enzyme in the mevalonate pathway within the liver. By blocking this specific molecular step, Lipomax directly suppresses the de novo production of cholesterol, alongside reducing the generation of essential non-sterol isoprenoid compounds, which initiates a cascade of downstream physiological events.

Increased Systemic LDL Catabolism and Vascular Modulation

The depletion of intracellular cholesterol triggers a compensatory response in the liver, leading to a significant upregulation of LDL Receptors on the cell surface, which mediates the cellular uptake of Low-Density Lipoprotein Cholesterol (LDL-C) from the systemic circulation. Concurrently, the reduction in isoprenoids (a consequence of the mevalonate blockade) modulates small regulatory GTPases, which modulates signaling proteins and downregulates pro-inflammatory pathway activity within the arterial walls. These actions collectively result in increased systemic lipid catabolism and modulation of vascular endothelial activity.

Dosage and Administration Information

How to Use Lipomax (Atorvastatin)

Lipomax (atorvastatin) is an oral medication taken once daily as a long-term therapy, with specific instructions for dosing and timing established according to official guidelines.

Administration Scope and Dosing

The medicine is administered orally in the form of a film-coated tablet, which should be swallowed whole. The medication can be taken once daily at any time of day, with or without food.

Feature Official Labeled Instruction
Standard Adult Dose Range 10 mg to 80 mg once daily, with initial doses typically being 10 mg or 20 mg.
Dose Titration Interval Dosage adjustments, if required, should occur at intervals of four weeks or more.
Renal Impairment No dose adjustment is required for patients with impaired kidney function.
Pediatric Use (HeFH, ge 10 years) Recommended starting dose is 10 mg once daily, with a maximum dose of 20 mg daily.

Procedural Constraints

The full prescribed dose is taken all at once. If a dose is missed, the recommended approach is to skip the missed dose and resume the regular schedule if it is almost time for the next dose; double dosing is not permitted. Additionally, there are documented maximum dose ceilings for atorvastatin when co-administered with specific strong inhibitors (e.g., clarithromycin, certain antivirals), which are detailed in the official product labeling to guide proper use. This framework dictates the standardized, long-term administration pattern for the drug.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lipomax (Atorvastatin)


Evidence for Reducing First Cardiovascular Events (Primary Prevention)

Research into Lipomax has been used to explore its application in individuals who are considered to have an elevated risk for heart disease but who do not have a history of heart attack or stroke. The major evidence base consists of large-scale, international Randomized Controlled Trials (RCTs). These studies monitored thousands of adult participants over several years, examining the occurrence of a first major cardiovascular event (MACE).

Studies monitored the occurrence of MACE and reported patterns of fewer events in the group studied compared to the control group during the primary trial period. What remains uncertain includes the potential application for individuals who fall into the lowest risk categories, as the trials typically focused on high-risk groups.


Evidence for Preventing Recurrent Heart Events (Secondary Prevention)

A substantial amount of research has examined the use of Lipomax in patients who already have established coronary heart disease, such as those with a history of a heart attack. Research examined the frequency of recurrent major events in the studied populations.

Outcomes studied included subsequent non-fatal heart attacks, subsequent strokes, and hospitalization for heart failure. Studies monitored participants and reported observations on the occurrence of recurrent events in the group studied over the median follow-up period. This area of evidence also focuses heavily on whether participants achieved specific, pre-defined levels for lipid biomarkers.


Evidence on Lipids and Blood Fat Biomarkers

The evidence for Lipomax also includes numerous controlled clinical trials designed to monitor changes in blood fat biomarkers. Researchers monitored changes in key substances, primarily focusing on the percent reduction of Low-Density Lipoprotein Cholesterol (LDL-C). Research highlights changes measured during the study period, with findings described measured shifts in the average LDL-C levels across various dose ranges in the populations studied.

Key Studies & References

  1. Efficacy and safety of statins for primary prevention of cardiovascular disease: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Lipomax (FAQ)

Q: How quickly should I expect to notice the effects of Lipomax?

A: Studies and official product information indicate that the lipid-lowering effects, specifically the reduction of LDL-C (often called 'bad' cholesterol), may be assessed by healthcare professionals as early as four weeks after beginning treatment. This time frame is often referenced by prescribers for assessing the response to treatment.

Q: What happens if I stop taking Lipomax suddenly?

A: Official labeling does not document a risk of addiction or specific withdrawal symptoms when stopping this medicine. However, stopping it without consulting a prescriber may result in cholesterol levels returning to previous, elevated levels, which reintroduces the long-term cardiovascular risk the medication is intended to manage.

Q: Does Lipomax have a generic equivalent?

A: Yes, the active ingredient in Lipomax is atorvastatin, which has been approved by regulatory bodies as a generic equivalent. This means that generic versions are available for this medicine.

Q: What's the difference between Lipomax and other common cholesterol medicines?

A: Lipomax is classified as a statin, which works by competitively inhibiting the enzyme HMG-CoA Reductase inside the liver. Other common medicines used to lower cholesterol, such as fibrates or bile acid sequestrants, belong to different pharmacological classes and operate through distinct mechanisms to control blood fat levels.

Q: What is the typical time frame for Lipomax to reach its full effect?

A: Official documents state that the full effect on reducing blood cholesterol levels, specifically LDL-C, is commonly assessed when clinically appropriate, often as early as four weeks after starting the medicine or adjusting the dose. This assessment helps determine the long-term effectiveness of the current treatment plan.

Q: Can Lipomax be cut in half or crushed?

A: Regulatory documents explicitly state that the film-coated tablets must not be crushed to preserve the medication's integrity. If a splitting is required for dosing, it is a practice that is reviewed by the prescriber.

Q: What is the difference between brand-name Lipomax and its generic version?

A: The brand-name product and its generic equivalent contain the identical active ingredient, which is atorvastatin. Generic products must meet regulatory standards for bioequivalence, meaning they are required to work in the body with the same quality, strength, and effect as the original brand-name medicine.

Q: What should I do if I think I'm having a bad interaction with Lipomax?

A: Official guidance emphasizes the importance of promptly consulting a healthcare professional if they experience symptoms suggesting a serious side effect or interaction. This includes symptoms such as unexplained muscle pain, weakness, or any signs of liver problems.

Q: How long does the body take to clear Lipomax after the last dose?

A: Pharmacokinetic data from regulatory documents indicates that the mean plasma elimination half-life (the time it takes for half of the active drug to leave the bloodstream) for the parent drug (atorvastatin) in humans is approximately 14 hours.

Q: Can I take Lipomax if I am currently taking aspirin?

A: Aspirin is not listed in the official regulatory drug interaction profile as having a major pharmacokinetic or pharmacodynamic interaction with Lipomax that requires a dose restriction. However, it is a practice that is typically reviewed by a healthcare provider.

Q: Does alcohol consumption affect how Lipomax works?

A: Official regulatory warnings note that patients who consume substantial quantities of alcohol or have a history of liver disease may be at an increased risk for hepatic injury (liver damage) while undergoing treatment with this medication.

Q: What happens if I accidentally miss a dose of Lipomax?

A: According to official instructions, if a dose is missed, patients are advised to skip the missed dose and resume the regular schedule with the next dose. It is strictly stated that double dosing is not permitted.

Q: Can Lipomax interact with common cold or flu medicines?

A: Regulatory interaction profiles generally focus on specific drugs that interfere with the CYP3A4 enzyme. While general cold or flu medicines are not listed as major interactions, the co-administration of such products is a topic for discussion with a healthcare professional, especially those containing ingredients metabolized by the liver.

Q: Is Lipomax safe for people with known allergies?

A: Lipomax is Contraindicated in individuals with known hypersensitivity or allergy to atorvastatin or any components of the medication. Regulatory documents primarily address hypersensitivity to the drug's components, not allergies to non-drug substances.

Q: How long does the feeling of relief from symptoms last after taking Lipomax?

A: Lipomax is a long-term preventative treatment designed to regulate blood fat levels and reduce cardiovascular risk over time. It is not intended to provide acute or immediate relief from symptoms, as its benefits are achieved through prolonged use.

Q: What regulatory body originally approved Lipomax?

A: Regulatory drug history indicates that the brand-name product containing atorvastatin was granted its Initial U.S. Approval by the FDA (Food and Drug Administration) in 1996.

Q: Is there a risk of developing a dependency on Lipomax?

A: Official regulatory profiles and safety sources provide no evidence suggesting that Lipomax is habit-forming or carries a risk of physical or psychological dependency.

Q: Are any long-term health risks associated with taking Lipomax?

A: Long-term regulatory safety communications have noted that the use of statins is associated with a small, increased risk of developing raised blood sugar levels and, in rare instances, the development of Type 2 diabetes. Extended therapy generally involves ongoing monitoring for changes in health indicators.

How should Lipomax be stored and disposed of?

Storage and Handling Constraints

The medicinal product does not require any special temperature conditions for storage. However, specific handling rules are mandatory to maintain product integrity and prevent unnecessary exposure.

Storage/Handling Constraint Requirement
Tablet Integrity The film-coated tablets must not be crushed.
Powder Contact If powder contacts the skin, the area should be washed immediately and thoroughly with soap and water. If contact is made with mucous membranes, they must be thoroughly flushed with water.
Disposal Classification Disposal of unused product and waste material must be carried out according to local requirements for cytotoxic medicinal products.

The official storage profile emphasizes strict handling to ensure containment and mandates specific decontamination procedures for powder exposure. Regulatory documents define disposal by requiring all waste be treated as controlled, hazardous waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipomax found in:

A-Z Index: